Company: SXTPW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003343
Chunk: 73

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1
Chunk 73
---
 possible
repeal and replacement could have on our business.

Most recently, on August 16, 2022, the Inflation
Reduction Act of 2022 was signed into law which provides for (i) the government to set or negotiate prices for select high-cost Medicare
Part D (beginning in 2026) and Medicare Part B drugs (beginning in 2028) that are more than nine years (for small-molecule drugs) or 13
years (for biological products) from their FDA approval, (ii) manufacturers to pay a rebate for Medicare Part B and Part D drugs when
prices increase faster than inflation beginning in 2022 for Medicare Part D and 2023 for Medicare Part B drugs, and (iii) Medicare Part
D redesign which replaces the current coverage gap provisions and establishes a $2,000 cap for out-of-pocket limits costs for Medicare
beneficiaries beginning in 2025, with manufacturers being responsible for 10% of costs up to the $2,000 cap and 20% after that cap is
reached.

Future indications for Arakoda may justify higher pricing in principle, but cumulative health-care reforms inclusive of the IRA limit
price increases and/or indication-based pricing without financial penalties if manufacturers’ products have Medicare coverage. The
impact of these reforms on the pharmaceutical industry generally is in its infancy, and will depend on how or if they are implemented
by regulators. We will monitor this issue to determine the effects of this legislation on our business – full implementation of
the reforms may have a negative impact on maximizing the profitability, but the actual impact at this juncture is uncertain.

38

Human Capital Resources

As of December 31, 2024, we had a total of three
employees, all of whom are full-time. We also utilize the services of two part-time contractors.

Our human capital resources objectives include,
as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and new employees, advisors and consultants.
The principal purposes of our equity and cash incentive plans are to attract, retain and reward personnel through the granting of stock-based
and cash-based compensation awards, in order to increase stockholder value and the success of our Company by motivating such individuals
to perform to the best of their abilities and achieve our objectives.

Available Information

Our website address is https://60degreespharma.com.
Our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form